Top

Published in:

01-06-2012 | Short Communication

Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya

Authors: Christine J. McGrath, Julia Njoroge, Grace C. John-Stewart, Pamela K. Kohler, Sarah F. Benki-Nugent, Joan W. Thiga, Anthony Etyang, Michael H. Chung

Published in: Journal of NeuroVirology | Issue 3/2012

Abstract

The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described. We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4T-based and 269 (15 %) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n = 236) among d4T users and 6.9 (n = 7) among ZDV users (P = 0.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P = 0.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.

Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP (1998) Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12:1735–1744PubMedCrossRef

Castelnuovo B, Kiragga A, Kamya MR, Manabe Y (2011) Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr 56:59–63PubMed

Cheng YJ, Gregg EW, Kahn HS, Williams DE, De Rekeneire N, Narayan KM (2006) Peripheral insensate neuropathy—a tall problem for US adults? Am J Epidemiol 164:873–880PubMedCrossRef

Cherry CL, Affandi JS, Imran D, Yunihastuti E, Smyth K, Vanar S, Kamarulzaman A, Price P (2009) Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 73:315–320PubMedCrossRef

Chung MH, Drake AL, Richardson BA, Reddy A, Thiga J, Sakr SR, Kiarie JN, Yowakim P, John-Stewart GC (2009) Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res 7:441–446PubMedCrossRef

Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O’Shaughnessy MV, Montaner JS (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346:811–820PubMedCrossRef

Dalakas MC (2001) Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6:14–20PubMedCrossRef

Dlamini J, Ledwaba L, Mokwena N, Mokhathi T, Orsega S, Tsoku M, Kowo H, Proschan M, Khabo P, Maja P, Hadigan C (2011) Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa. Antivir Ther 16:605–609PubMedCrossRef

Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, Gelman BB, Vaida F, Collier A, Marra CM, Ances B, Atkinson JH, Dworkin RH, Morgello S, Grant I (2010) Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol 67:552–558PubMedCrossRef

Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks JT, Weidle PJ (2007) Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 44:456–462PubMedCrossRef

Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R (2007) Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 45:304–310PubMed

Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, Audu RA, Araoyinbo ID, Onyewuche JI, Salu OB, Adedoyin JA, Musa AZ (2005) Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 40:65–69PubMedCrossRef

Karara MW, Okalebo FA, Oluka MN, Ombega J, Guantai AN, Osanjo GO (2010) Comparative tolerability and efficacy of stavudine 30 mg versus stavudine 40 mg in patients on combination antiretroviral therapy in Kenya. J AIDS HIV Res 2:24–31

Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liegeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngole E, Delaporte E (2004) Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364:29–34PubMedCrossRef

Laurent C, Bourgeois A, Mpoudi-Ngole E, Ciaffi L, Kouanfack C, Mougnutou R, Nkoue N, Calmy A, Koulla-Shiro S, Delaporte E (2008) Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses 24:393–399PubMedCrossRef

Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD (2005) Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 40:148–157PubMedCrossRef

Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Moorman AC, Wood KC, Holmberg SD, Brooks JT (2008) Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 47:27–35PubMedCrossRef

Moyle GJ, Sadler M (1998) Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 19:481–494PubMedCrossRef

Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB (2009) Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 72:165–170PubMedCrossRef

Scarsella A, Coodley G, Shalit P, Anderson R, Fisher RL, Liao Q, Ross LL, Hernandez JE (2002) Stavudine-associated peripheral neuropathy in zidovudine-naive patients: effect of stavudine exposure and antiretroviral experience. Adv Ther 19:1–8PubMedCrossRef

Simpson DM, Tagliati M (1995) Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 9:153–161PubMed

Wadley AL, Cherry CL, Price P, Kamerman PR (2011) HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J Pain Symptom Manage 41:700–706PubMedCrossRef

Watters MR, Poff PW, Shiramizu BT, Holck PS, Fast KM, Shikuma CM, Valcour VG (2004) Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 62:1378–1383PubMedCrossRef

Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, Makhema J, van Widenfelt E, Musonda R, Novitsky V, Gaolathe T, Ndwapi N, Essex M, Kuritzkes DR, DeGruttola V, Marlink RG (2007) Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 46:318–322PubMedCrossRef

WHO (2009) Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. World Health Organization, Geneva

WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. World Health Organization, Geneva

WHO, UNAIDS, UNICEF (2009) Towards universal access: scaling up of priority HIV/AIDS interventions in the health sector: progress report 2009. World Health Organization, Geneva

Title: Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya
Authors: Christine J. McGrath
Julia Njoroge
Grace C. John-Stewart
Pamela K. Kohler
Sarah F. Benki-Nugent
Joan W. Thiga
Anthony Etyang
Michael H. Chung
Publication date: 01-06-2012
Publisher: Springer US
Published in: Journal of NeuroVirology / Issue 3/2012
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-012-0098-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Cytokine levels in CSF and neuropsychological performance in HIV patients

A diffusion tensor imaging and neurocognitive study of HIV-positive children who are HAART-naïve “slow progressors”

Direct evidence that HSV DNA damaged by ultraviolet (UV) irradiation can be repaired in a cell type-dependent manner

Differential expression and HIV-1 regulation of μ-opioid receptor splice variants across human central nervous system cell types

Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes—a retrospective study from a large urban cohort in Johannesburg, South Africa

Microglia activation by SIV-infected macrophages: alterations in morphology and cytokine secretion